Instil Bio Inc. (TIL)
NASDAQ: TIL
· Real-Time Price · USD
12.65
-0.20 (-1.56%)
At close: May 01, 2025, 3:59 PM
13.24
4.62%
After-hours: May 01, 2025, 04:59 PM EDT
Company Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer.
The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL).
Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others.
The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Instil Bio Inc.
| Country | United States |
| IPO Date | Mar 19, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Bronson Crouch |
Contact Details
Address: 3963 Maple Avenue Dallas, Texas United States | |
| Website | https://instilbio.com |
Stock Details
| Ticker Symbol | TIL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001789769 |
| CUSIP Number | 45783C101 |
| ISIN Number | US45783C2008 |
| Employer ID | 83-2072195 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Bronson Crouch | Chairman & Chief Executive Officer |
| Dr. Sandeep Laumas M.D. | Chief Financial Officer & Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2025 | 4 | Filing |
| Apr 28, 2025 | 4 | Filing |
| Apr 14, 2025 | ARS | Filing |
| Apr 14, 2025 | DEFA14A | Filing |
| Apr 14, 2025 | DEF 14A | Filing |
| Mar 31, 2025 | 424B5 | Filing |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 04, 2025 | S-8 | Filing |
| Mar 04, 2025 | 10-K | Annual Report |
| Mar 04, 2025 | 8-K | Current Report |